Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis

Creative Commons License

Atas N., Varan O., Babaoglu H., SATIŞ H., Bilici Salman R., TUFAN A.

ARCHIVES OF RHEUMATOLOGY, vol.34, no.3, pp.357-362, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.5606/archrheumatol.2019.7177
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.357-362
  • Keywords: Anti-tumor necrosis factor, certolizumab pegol, pregnancy, Takayasu arteritis, ANTITUMOR NECROSIS FACTOR, PLACENTAL-TRANSFER, CASES SERIES, MULTICENTER, INHIBITORS, ALPHA
  • Gazi University Affiliated: Yes


Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease. The onset of TA is generally observed in females of reproductive age. Certolizumab pegol (CZP) lacks a fragment crystallizable region and this gives advantage of minimal transfer through the placenta, which makes CZP a safer option in pregnancy. Although there are case reports and trials about use of infliximab, etanercept, and adalimumab in TA, there are scarce data about use of CZP. In this article, we present three TA cases treated with CZP. While two patients benefited from CZP, one patient was refractory to CZP.